• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Patients' Perspectives on Coming Off Opioid Agonist Treatment: A Qualitative Study.患者对停用阿片类激动剂治疗的看法:一项定性研究。
Subst Abuse. 2022 Jun 21;16:11782218221107021. doi: 10.1177/11782218221107021. eCollection 2022.
2
Caregivers' Attitudes Toward Treatment Length for Persons in Swedish Opioid Agonist Treatment. A Qualitative Interview Study.照顾者对瑞典阿片类激动剂治疗者治疗时长的态度。一项定性访谈研究。
J Psychoactive Drugs. 2024 Jul-Aug;56(3):373-379. doi: 10.1080/02791072.2023.2228794. Epub 2023 Jun 23.
3
Prolonged-release opioid agonist therapy: qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations.长效阿片类激动剂治疗:探索患者对丁丙诺啡 1 周、1 个月和 6 个月制剂看法的定性研究。
Harm Reduct J. 2019 Apr 3;16(1):25. doi: 10.1186/s12954-019-0296-4.
4
The Accessibility of Opioid Agonist Treatment and Its Forced Discontinuation in Swiss Prisons-Attitudes, Perceptions and Experiences of Defense Lawyers in Dealing With Detained Persons Using Opioids.瑞士监狱中阿片类激动剂治疗的可及性及其强制中断——辩护律师在处理使用阿片类药物的被拘留者时的态度、认知和经历
Front Psychiatry. 2020 May 14;11:395. doi: 10.3389/fpsyt.2020.00395. eCollection 2020.
5
Methadone and buprenorphine treatment in United States jails and prisons: lessons from early adopters.美国监狱中美沙酮和丁丙诺啡治疗:早期采用者的经验教训。
Addiction. 2021 Dec;116(12):3473-3481. doi: 10.1111/add.15565. Epub 2021 May 25.
6
Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.加拿大安大略省患有阿片类药物使用障碍(OUD)的联邦监狱服刑人员的阿片类激动剂治疗(OAT)经历与释放计划:一项混合方法研究
BMC Public Health. 2022 Mar 4;22(1):436. doi: 10.1186/s12889-022-12685-0.
7
Mal/adaptations: A qualitative evidence synthesis of opioid agonist therapy during major disruptions.适应不良:重大干扰期间阿片类激动剂治疗的定性证据综合。
Int J Drug Policy. 2022 Mar;101:103556. doi: 10.1016/j.drugpo.2021.103556. Epub 2021 Dec 11.
8
What features of drug treatment programs help, or not, with access? a qualitative study of the perspectives of family members and community-based organization staff in Atlantic Canada.药物治疗项目的哪些特点有助于(或无助于)获得治疗?对加拿大大西洋地区家庭成员和社区组织工作人员观点的定性研究。
Subst Abuse Treat Prev Policy. 2024 Mar 22;19(1):20. doi: 10.1186/s13011-024-00602-0.
9
Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.阿片类激动剂治疗与阿片类药物过量公共卫生紧急情况下的死亡率之间的关系:基于人群的回顾性队列研究。
BMJ. 2020 Mar 31;368:m772. doi: 10.1136/bmj.m772.
10
Opioid agonist therapy trajectories among street entrenched youth in the context of a public health crisis.公共卫生危机背景下街头长期吸毒青年的阿片类激动剂治疗轨迹
SSM Popul Health. 2020 Jun 4;11:100609. doi: 10.1016/j.ssmph.2020.100609. eCollection 2020 Aug.

引用本文的文献

1
What is the ideal time to begin tapering opioid agonist treatment? A protocol for a retrospective population-based comparative effectiveness study in British Columbia, Canada.开始逐渐减少阿片类激动剂治疗的理想时间是什么?加拿大不列颠哥伦比亚省一项基于人群的回顾性比较有效性研究的方案。
BMJ Open. 2024 Apr 29;14(4):e083453. doi: 10.1136/bmjopen-2023-083453.
2
Patient reported goals for medications for opioid use disorder: A theory of proximal goal attainment.患者报告的阿片类物质使用障碍药物治疗目标:近端目标达成理论
Explor Res Clin Soc Pharm. 2023 Oct 6;12:100345. doi: 10.1016/j.rcsop.2023.100345. eCollection 2023 Dec.

本文引用的文献

1
Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials.阿片类激动剂治疗的维持:观察性研究和随机对照试验比较的快速综述和荟萃分析。
Syst Rev. 2021 Aug 6;10(1):216. doi: 10.1186/s13643-021-01764-9.
2
Plausibility of patient-centred care in high-intensity methadone treatment: reflections of providers and patients.高剂量美沙酮治疗中以患者为中心护理的合理性:提供者和患者的反思。
Addict Sci Clin Pract. 2021 Jun 29;16(1):42. doi: 10.1186/s13722-021-00251-9.
3
The "black box" of treatment: Patients' perspective on what works in opioid maintenance treatment for opioid dependence.治疗的“黑箱”:患者对阿片类药物维持治疗治疗阿片类药物依赖的有效性的看法。
Subst Abuse Treat Prev Policy. 2021 May 10;16(1):41. doi: 10.1186/s13011-021-00378-7.
4
Opioid use disorder in pregnancy: leveraging provider perceptions to inform comprehensive treatment.孕期阿片类药物使用障碍:利用医护人员的认知为综合治疗提供依据。
BMC Health Serv Res. 2021 Mar 10;21(1):215. doi: 10.1186/s12913-021-06182-0.
5
Are patients' goals in treatment associated with expected treatment outcomes? Findings from a mixed-methods study on outpatient pharmacological treatment for opioid use disorder.患者的治疗目标是否与预期的治疗结果相关?一项关于门诊阿片类药物使用障碍药物治疗的混合方法研究的结果。
BMJ Open. 2021 Jan 12;11(1):e044017. doi: 10.1136/bmjopen-2020-044017.
6
Discontinuing Methadone and Buprenorphine: A Review and Clinical Challenges.美沙酮和丁丙诺啡的停药问题:综述及临床挑战。
J Addict Med. 2021;15(6):454-460. doi: 10.1097/ADM.0000000000000789.
7
A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.对患者和医疗服务提供者关于阿片类物质使用障碍治疗药物观点的系统评价。
J Subst Abuse Treat. 2020 Dec;119:108146. doi: 10.1016/j.jsat.2020.108146. Epub 2020 Sep 22.
8
Learning from Gothenburg model of person centred healthcare.借鉴哥德堡以患者为中心的医疗保健模式。
BMJ. 2020 Sep 1;370:m2738. doi: 10.1136/bmj.m2738.
9
A call for consensus in defining efficacy in clinical trials for opioid addiction: combined results from a systematic review and qualitative study in patients receiving pharmacological assisted therapy for opioid use disorder.呼吁在阿片类药物成瘾临床试验中定义疗效的共识:接受药物辅助治疗阿片类药物使用障碍的患者进行系统评价和定性研究的综合结果。
Trials. 2020 Jan 6;21(1):30. doi: 10.1186/s13063-019-3995-y.
10
Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review.概念化以患者为中心的物质使用障碍治疗方法:系统范围综述的结果。
Subst Abuse Treat Prev Policy. 2019 Sep 11;14(1):37. doi: 10.1186/s13011-019-0227-0.

患者对停用阿片类激动剂治疗的看法:一项定性研究。

Patients' Perspectives on Coming Off Opioid Agonist Treatment: A Qualitative Study.

作者信息

Nehlin Christina, Bäckström Josefin, Brander Charlotte Wollert, Öster Caisa

机构信息

Department of Medical Sciences, Psychiatry, Uppsala University, Uppsala, Sweden.

Division of Psychiatry, Uppsala University Hospital, Uppsala, Sweden.

出版信息

Subst Abuse. 2022 Jun 21;16:11782218221107021. doi: 10.1177/11782218221107021. eCollection 2022.

DOI:10.1177/11782218221107021
PMID:35754979
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9218892/
Abstract

AIMS

Opioid agonist treatment (OAT) programs are life-saving, as they reduce opioid use, overdoses, and criminal activities. Disadvantages reported with long-term OAT include side effects of the medication, especially on cognitive ability and sexual function, which may discourage potential participants. Many of those who participate in OAT have a desire to come off treatment. The aims of this study were to explore patients' thoughts about coming off OAT and to investigate their perceptions of what support they would need in order to realize a planned withdrawal from OAT.

METHODS

A qualitative interview study with semi-structured interviews, using applied thematic analysis. Persons with experiences of participating in OAT were invited from Swedish programs and a private Facebook community.

RESULTS

Fifteen persons, with a mean of 9.6 (±6.4) years of treatment experience, were included. The participants underlined the need for a patient-centered focus within the treatment. They wanted to be regarded as capable of deciding if, when, and how a planned ending was to take place. They also called for staff to be supportive in making such decisions. Participants recommended staff to be sensitive to the needs of the specific patient and to have strategies for coming off OAT that could be adjusted for the single person.

CONCLUSIONS

OAT programs need to be continually updated and adapted to the persons who can benefit from them. Applying a person-centered, holistic perspective would enhance the quality of the treatment by emanating from individual goals. Regulatory guidelines need to take into account research on patient experiences and perspectives on coming off.

摘要

目的

阿片类激动剂治疗(OAT)项目可挽救生命,因为它们能减少阿片类药物使用、过量用药及犯罪活动。长期OAT的缺点包括药物副作用,尤其是对认知能力和性功能的影响,这可能会使潜在参与者望而却步。许多参与OAT的人都希望停止治疗。本研究的目的是探讨患者对停止OAT的想法,并调查他们对于为实现有计划地从OAT中退出所需支持的看法。

方法

采用应用主题分析法进行半结构化访谈的定性研究。从瑞典的项目和一个私人脸书社区中邀请有OAT参与经历的人。

结果

纳入了15人,平均治疗经验为9.6(±6.4)年。参与者强调治疗中需要以患者为中心。他们希望被视为有能力决定是否、何时以及如何进行有计划的结束。他们还呼吁工作人员在做出此类决定时给予支持。参与者建议工作人员对特定患者的需求保持敏感,并拥有可针对个体进行调整的OAT停药策略。

结论

OAT项目需要不断更新并适应能从中受益的人群。采用以患者为中心的整体视角,从个体目标出发,将提高治疗质量。监管指南需要考虑关于患者停药经历和观点的研究。